Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02854631 · ClinicalTrials.gov registry record · Phase 2
Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
A Phase 2 study of Alcoholic Hepatitis (AH), sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT02854631 is a Phase 2 study of Alcoholic Hepatitis (AH) that has completed, run by Gilead Sciences. The registered enrollment target is 104 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02854631, a Phase 2 study of Alcoholic Hepatitis (AH), has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisolone
- DRUG Selonsertib
Study Locations (20)
Other
- Medizinische Universitat Graz - Graz
- Universitätsklinik für Innere Medizin I - Innsbruck
- Medical University Vienna - Vienna
- Cliniques Universitaires UCL Saint-Luc - Brussels
- CUB Hopital Erasme - Brussels
- Ghent University Hospital - Ghent
- Universitair Ziekenhuis Leuven - Leuven
- Centre Hospitalier Universitaire de Liege - Liège
California
- Southern California Research Centers - Coronado
- Cedars Sinai Medical Center - Los Angeles
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- Cleveland Clinic Florida - Weston
Louisiana
- Oschner Medical Center - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02854631
The ClinicalTrials.gov registry entry for NCT02854631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholic Hepatitis (AH) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02854631 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02854631 about?
NCT02854631 is a clinical study titled "Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)". The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).
What is the current status of trial NCT02854631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2016-09-01. Estimated completion is 2018-05-31.
What conditions does trial NCT02854631 study?
This clinical trial studies the following conditions: Alcoholic Hepatitis (AH).
What interventions are being tested in trial NCT02854631?
The interventions under investigation include: Placebo (DRUG), Prednisolone (DRUG), Selonsertib (DRUG).
Who is sponsoring clinical trial NCT02854631?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02854631 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.